Epizyme Gets a Buy Rating from Oppenheimer


In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $25. The company’s shares closed yesterday at $16.25.

Cann observed:

“In ASCO Abstract #8515 released on Epizyme reported new clinical data from a phase I study of tazemetostat in patients with relapsed or refractory mesothelioma. Tazemetostat is currently being studied in clinical programs in INI-1 negative tumors, synovial sarcomas, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and mesothelioma. The data released today support tazemetostat’s potential in mesothelioma and support our expectations for launch.”

According to TipRanks.com, Cann is a 5-star analyst with an average return of 16.9% and a 58.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.

Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.13, representing a 48.5% upside.

In a report issued on May 8, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.40 and a one-year low of $9.30. Currently, Epizyme has an average volume of 403.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Develops therapeutics for the treatment of patients with genetically defined cancers

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts